Assembly Biosciences (NASDAQ:ASMB) Rating Increased to Strong-Buy at UBS Group

Assembly Biosciences (NASDAQ:ASMB) was upgraded by analysts at UBS Group to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Mizuho set a $53.00 target price on Assembly Biosciences in a research note on Tuesday. Zacks Research upgraded Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $45.60.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $35.18 on Tuesday. Assembly Biosciences has a one year low of $20.23 and a one year high of $39.71. The business’s 50 day simple moving average is $28.55 and its two-hundred day simple moving average is $28.00. The stock has a market capitalization of $716.26 million, a P/E ratio of 34.49 and a beta of 1.12.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The company had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Sell-side analysts expect that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new stake in Assembly Biosciences during the 2nd quarter valued at approximately $103,000. Seven Fleet Capital Management LP lifted its stake in shares of Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after purchasing an additional 377,000 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Assembly Biosciences in the 2nd quarter valued at approximately $660,000. Bank of America Corp DE boosted its position in shares of Assembly Biosciences by 113.3% during the first quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 5,792 shares in the last quarter. Finally, Stempoint Capital LP grew its stake in Assembly Biosciences by 18.3% in the first quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after purchasing an additional 28,707 shares during the period. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.